|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Intensified intensity-modulated radiotherapy in anal cancer with prevalent HPV p16 positivity显示文摘AIM: To investigate the toxicity and response of intensity-modulated radiotherapy schedule intensified with a simultaneous integrated boost in anal canal cancer.METHODS: From March 2009 to March 2014, we retrospectively analyzed 41 consecutive patients treated with intensity-modulated radiotherapy(IMRT) and concurrent chemotherapy for anal canal squamous cell carcinoma at our center. Radiotherapy was delivered via simultaneous integrated boost(SIB) technique by helical tomotherapy, and doses were adapted to two clinical target volumes according to the tumor-nodemetastasis(TNM) stage: 50.6 Gy and 41.4 Gy in 23 fractions in T1N0, 52.8 Gy and 43.2 Gy in 24 fractionsin T2N0, and 55 Gy and 45 Gy in 25 fractions in all patients with N positive and/or ≥ T3, respectively, to planning target volumes 1 and 2. The most common chemotherapy regimen was 5-fluorouracil and mitomycin-based. Human papilloma virus(HPV) p16 expression was performed by immunohistochemistry and evaluated in the majority of patients. Acute and late toxicity was scored according to CTCAe v 3.0 and RTOG scales.RESULTS: The median follow-up was 30 mo(range:12-71). Median age was 63 years(range 32-84). The stage of disease was: stage Ⅰ in 2 patients, stage Ⅱin 13 patients, stage ⅢA in 12 patients, and stage ⅢB in 14 patients, respectively. Two patients were known to be HIV positive(4.9%). HPV p16 expression status was positive in 29/34(85.3%) patients. The 4-year progression-free survival and overall survival in HPVpositive patients were 78% and 92%, respectively.Acute grade 3 skin and gastrointestinal toxicities were reported in 5% and 7.3% of patients, respectively;patients' compliance to the treatment was good due to a low occurrence of severe acute toxicity, although treatment interruptions due to toxicity were required in 7.3% of patients. At 6 mo from end of treatment,36/40(90%) patients obtained complete response;during follow-up, 5(13.8%) patients presented with disease progression(local or systemic).CONCLUSION: In our experience, intensified SIBIMRT with chemotherapy is very feasible in clinical practice, with excellent results in terms of overall survival and local control. | Liliana Belgioia Stefano Vagge Dario Agnese Stefania Garelli Roberto Murialdo Giuseppe Fornarini Silvana Chiara Fabio Gallo Almalina Bacigalupo Renzo Corvò | 2015 | World Journal of Gastroenterology2015，21，37： | 2 |
| 2 | Adhesion to Mac2- BP ( Mae-2 BP) as a mechanism for lymphoma drug resistance in vivo显示文摘 | Fornarini B D'Ambrosio C Natoli C | 2000 | Blood2000，96，9： | 1 |
| 3 | Adhesion to 90K(Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo显示文摘 | Fornarini B D'Ambrosio C Natoli C | 2000 | Blood2000，96，9： | 1 |
| 4 | Positive ion chemistry of elemental fluorine显示文摘 | CIPOLLINI R CRESTONI M E FORNARINI S | 1997 | J Am Chem Soc1997，119，： | 1 |
| 5 | 查看详情显示文摘 | Crestoni M E Fornarini S | | 0，，： | 1 |
| 6 | Contribution of germline mutations in the BRCA and PALB2 genes to pancreatic cancer in Italy显示文摘 | P. Ghiorzo V. Pensotti G. Fornarini S. Sciallero L. Battistuzzi F. Belli L. Bonelli G. Borgonovo W. Bruno A. Gozza S. Gargiulo L. Mastracci S. Nasti G. Palmieri F. Papadia L. Pastorino A. Russo V. Savarino L. Varesco L. Bernard G. Bianchi Scarrà | 2012 | Familial Cancer2012，，1： | 1 |
| 7 | Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo显示文摘 | Fornarini B Ambrosio CD Natoli C | 2000 | Blood2000，96，9： | 1 |
| 8 | Realisation and characterisation of LiF/NaF thin film planar waveguides显示文摘 | Fornarini L Martelli S Montereali R M | 2000 | Thin Solid Films2000，358，： | 1 |
| 9 | Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo显示文摘 | Fornarini B D'Ambrosio C Natoli C | 2000 | Blood2000，96，9： | 1 |
| 10 | Adhesion to 90K (Mac 2BP) as a mechanism for lymphoma drug resist- ance in vivo显示文摘 | Fornarini B D'Ambrosio C Natoli C | 2000 | Blood2000，96，9： | 1 |
| 11 | Pemetrexed in gastric cancer显示文摘 | Sobrero A Caprioni F Fornarini G | 2004 | Oncology2004，18，138： | 1 |
| 12 | Signs and genetics of rare cancer syndromes with gastroenterological features显示文摘Although the genetic bases of most hereditary cancer syndromes are known,and genetic tests are available for them,the incidence of the most rare of these syndromes is likely underestimated,partially because the clinical expression is neither fully understood nor easily diagnosed due to the variable and complex expressivity. The clinical features of a small pool of rare cancer syndromes include gastroenterological signs,though not necessarily tumors,that could require the intervention of a gastroenterologist during any of the phases of the clinical management. Herein we will attempt to spread the knowledge on these rare syndromes by summarizing the phenotype and genetic basis,and revising the peculiar gastroenterological signs whose underlying role in these rare hereditary cancer syndromes is often neglected. Close collaboration between geneticists and gastroenterologists could facilitate both the early identification of patients or relatives at-risk and the planning of multidisciplinary and tailored management of these subjects. | William Bruno Giuseppe Fornarini Paola Ghiorzo | 2015 | World Journal of Gastroenterology2015，21，30： | 0 |
| 13 | Role of conventional therapies in the era of biological treatment in Crohn’s disease显示文摘Outstanding progress regarding the pathophysiology of Crohn's disease (CD) has led to the development of innovative therapeutic concepts. Numerous controlled trials have been performed in CD. This review concentrates on the results of randomized,placebo-controlled trials,and meta-analyses when available,that provide the highest degree of evidence. Current guidelines on the management of CD recommend a step-up approach to treatment involving the addition of more powerful therapies as the severity of disease and refractoriness to therapy increase. The advent of biological drugs has opened new therapeutic horizons for treating CD,modifying the treatment goals. However,the large majority of patients with CD will be managed through conventional therapy,even if they are a prelude to biological therapy. | Paolo Gionchetti Carlo Calabrese Rosy Tambasco Ramona Brugnera Giulia Straforini Giuseppina Liguori Giulia Spuri Fornarini Donatella Riso Massimo Campieri Fernando Rizzello | 2011 | World Journal of Gastroenterology2011，17，14： | 0 |
| 14 | First-line pazopanib in patients with advanced non-clear cell renal carcinoma:An Italian case series显示文摘BACKGROUND Non-clear cell(ncc)metastatic renal-cell carcinoma(RCC)has dismal results with standard systemic therapies and a generally worse prognosis when compared to its clear-cell counterpart.New systemic combination therapies have emerged for metastatic RCC(mRCC),but the pivotal phase III trials excluded patients with nccRCC,which constitute about 30%of metastatic RCC cases.AIM To provide a piece of real-life evidence on the use of pazopanib in this patient subgroup.METHODS The present study is a multicenter retrospective observational analysis aiming to assess the activity,efficacy,and safety of pazopanib as first-line therapy for advanced nccRCC patients treated in a real-life setting.RESULTS Overall,48 patients were included.At the median follow-up of 40.6 mo,the objective response rate was 27.1%,the disease control rate was 83.3%,and the median progression-free survival and overall survival were 12.3(95%confidence interval[CI]:3.6-20.9)and 27.7(95%CI:18.2-37.1)mo,respectively.Grade 3 adverse events occurred in 20%of patients,and no grade 4 or 5 toxicities were found.CONCLUSION Pazopanib should be considered as a good first-line option for metastatic RCC with variant histology. | Sebastiano Buti Melissa Bersanelli Francesco Massari Ugo De Giorgi Orazio Caffo Gaetano Aurilio Umberto Basso Giacomo Carteni Claudia Caserta Luca Galli Francesco Boccardo Giuseppe Procopio Gaetano Facchini Giuseppe Fornarini Alfredo Berruti Elena Fea Emanuele Naglieri Fausto Petrelli Roberto Iacovelli Camillo Porta Alessandra Mosca | 2021 | World Journal of Clinical Oncology2021，12，11： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员